文献速递临床试验与 GCP基础与转化研究

二甲双胍增强老年人力量训练有效应答(MASTERS):一项随机对照试验的研究方案

Metformin to Augment Strength Training Effective Response in Seniors (MASTERS): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-04-26

本研究为两中心、随机、双盲、安慰剂对照试验,纳入65岁及以上个体,在14周渐进性抗阻训练前2周开始每日服用二甲双胍1700 mg或安慰剂并持续至训练结束,评估二甲双胍对肌肉大小、力量和躯体功能的影响。这是首个在非患病人群中针对抗阻训练无应答表型进行的二甲双胍老药新用试验。

要点

  • 65岁及以上个体随机接受每日二甲双胍1700 mg或安慰剂,联合14周渐进性抗阻训练。
  • 主要评估二甲双胍组是否较安慰剂组在肌肉量与力量增益上获得更大整体获益。
  • 在三个时间点取股外侧肌活检,评估细胞与分子适应及对二甲双胍的应答变化。

核心结论

  • 本试验旨在确定运动联合二甲双胍干预是否能通过促进肌肉肥大和力量增益使老年人获益,从而维持功能独立。

研究设计与样本

  • 两中心、随机、双盲、安慰剂对照试验,纳入65岁及以上个体。
  • 参与者在14周渐进性抗阻训练方案前2周每日服用二甲双胍1700 mg或安慰剂,训练期间继续服用。
  • 在三个时间点取股外侧肌活检以评估细胞与分子适应及对二甲双胍的应答变化。

主要发现

  • 研究方案未报告结果数据。

关键数值与推荐

  • 二甲双胍剂量为每日1700 mg,安慰剂对照。
  • 抗阻训练方案为14周渐进性抗阻训练,训练前2周开始用药。
  • 肌肉活检取自股外侧肌,共三个时间点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Muscle mass and strength are strong determinants of a person's quality of life and functional independence with advancing age. While resistance training is the most effective intervention to combat age-associated muscle atrophy (sarcopenia), the ability of older adults to increase muscle mass and strength in response to training is blunted and highly variable. Thus, finding novel ways to complement resistance training to improve muscle response and ultimately quality of life among older individuals is critical. The purpose of this study is to determine whether a commonly prescribed medication called metformin can be repurposed to improve the response to resistance exercise training by altering the muscle tissue inflammatory environment. METHODS/DESIGN: Individuals aged 65 and older are participating in a two-site, randomized, double-blind, placebo-controlled trial testing the effects of metformin or placebo on muscle size, strength, and physical function when combined with a progressive resistance training program. Participants consume 1700 mg of metformin per day or placebo for 2 weeks before engaging in a 14-week progressive resistance training regimen, with continued metformin or placebo. Participants are then monitored post-training to determine if the group taking metformin derived greater overall benefit from training in terms of muscle mass and strength gains than those on placebo. Muscle biopsies are taken from the vastus lateralis at three time points to assess individual cellular and molecular adaptations to resistance training and also changes in response to metformin. DISCUSSION: The response of aged muscles to a resistance training program does not always result in a positive outcome; some individuals even experience a loss in muscle mass following resistance training. Thus, adjuvant therapies, including pharmacological ones, are required to optimize response to training in those who do not respond and may be at increased risk of frailty. This is the first known metformin repurposing trial in non-diseased individuals, aimed specifically at the resistance exercise "non-responder" phenotype present in the aging population. The overall goal of this trial is to determine if combined exercise-metformin intervention therapy will benefit older individuals by promoting muscle hypertrophy and strength gains, thereby maintaining functional independence. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02308228 . Registered on 25 November 2014.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Long DE, Peck BD, Martz JL, et al. Metformin to Augment Strength Training Effective Response in Seniors (MASTERS): study protocol for a randomized controlled trial. Trials. 2017. PMID: 28441958. doi:10.1186/s13063-017-1932-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。